Netflix Inc. has secured exclusive U.S. rights to new movies from Sony Pictures after they leave theaters, in a multiyear agreement giving the streaming giant upcoming films in the popular “Jumanji” and “Spider-Man” franchises.
The entertainment division of Japan’s Sony Corp. has also given Netflix the first chance to buy movies that aren’t headed for theaters and take part in their production, another potential pipeline of original films.
Financial terms of the deal announced Thursday weren’t disclosed, though Bloomberg News previously reported Sony was seeking as much as $250 million a year.
The titles from Sony include some of the most-popular film franchises at the box office year in and year out. Netflix will also be the streaming home for “Morbius,” a spinoff of “Spider-Man,” as well as “Where the Crawdads Sing,” an adaptation of the bestselling novel.
The agreement starts with Sony’s 2022 movie slate. Sony’s previous pay-TV deal was with Starz, owned by Lions Gate Entertainment Corp.
Shares in Netflix rose as much as 1.8% to $556.90 in New York after the news, their highest in more than a month. Lionsgate also briefly spiked, rising as high as $16.28, before retreating.
These titles won’t attract millions of new subscribers to Netflix, which already releases nearly 60 original movies a year. But they do keep users entertained in between new series. Netflix previously offered new movies from Walt Disney Co., until the studio decided to keep its movies on Disney+.
Sony is the only major Hollywood studio not owned by a company that competes with Netflix in streaming. Universal, owned by Comcast Corp., is weighing whether to renew a deal with HBO Max or keep its movies for Peacock.
Netflix didn’t say how long Sony’s movies would play in theaters before they appear on the streaming platform. Other movie studios have shortened the time between theatrical and home viewing, but the delay may increase when COVID-19 cases fall and theaters are reopened worldwide.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.